NASDAQ:LGND - Ligand Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $177.40
  • Forecasted Upside: 66.79 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$106.36
▲ +4.39 (4.31%)

This chart shows the closing price for LGND by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ligand Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LGND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LGND

Analyst Price Target is $177.40
▲ +66.79% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ligand Pharmaceuticals in the last 3 months. The average price target is $177.40, with a high forecast of $310.00 and a low forecast of $130.00. The average price target represents a 66.79% upside from the last price of $106.36.

This chart shows the closing price for LGND for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Ligand Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/5/2022BarclaysLower Price TargetOverweight$165.00 ➝ $157.00N/A
6/16/2022BMO Capital MarketsInitiated CoverageOutperformHigh
5/16/2022StephensLower Price TargetNA$130.00N/A
5/5/2022Craig HallumLower Price Target$215.00 ➝ $160.00High
2/22/2022BenchmarkLower Price TargetBuy$180.00 ➝ $130.00High
2/18/2022BarclaysLower Price TargetOverweight$185.00 ➝ $165.00High
12/22/2021HC WainwrightReiterated RatingBuy$310.00High
9/22/2021BarclaysBoost Price TargetOverweight$174.00 ➝ $180.00Low
9/14/2021HC WainwrightReiterated RatingBuy$310.00Low
8/31/2021HC WainwrightReiterated RatingBuy$310.00High
7/30/2021Roth CapitalLower Price TargetBuy$200.00 ➝ $190.00High
7/19/2021HC WainwrightReiterated RatingBuy$310.00Medium
5/4/2021BarclaysLower Price TargetOverweight$198.00 ➝ $190.00High
4/14/2021StephensInitiated CoverageOverweightHigh
2/4/2021Craig HallumBoost Price Target$195.00 ➝ $215.00Medium
2/4/2021Roth CapitalBoost Price TargetBuy$195.00 ➝ $200.00Medium
2/4/2021BarclaysBoost Price TargetOverweight$145.00 ➝ $198.00Low
2/4/2021HC WainwrightBoost Price TargetBuy$229.00 ➝ $310.00Low
10/21/2020Craig HallumLower Price TargetBuy$215.00 ➝ $195.00High
10/6/2020BarclaysInitiated CoverageOverweight$156.00Medium
9/29/2020Roth CapitalBoost Price TargetBuy$190.00 ➝ $195.00Low
8/14/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/11/2020HC WainwrightReiterated RatingBuy$229.00High
8/4/2020Roth CapitalBoost Price TargetBuy$180.00 ➝ $190.00Medium
8/4/2020BarclaysBoost Price TargetOverweight$134.00 ➝ $145.00Medium
8/3/2020HC WainwrightReiterated RatingBuy$229.00Medium
7/14/2020BenchmarkBoost Price TargetBuy$135.00 ➝ $155.00Low
6/15/2020HC WainwrightReiterated RatingBuy$229.00Low
5/29/2020HC WainwrightReiterated RatingBuy$229.00Low
4/8/2020HC WainwrightLower Price Target$237.00 ➝ $229.00High
4/6/2020HC WainwrightLower Price TargetBuy$237.00 ➝ $229.00Medium
3/24/2020ArgusDowngradeBuy ➝ HoldHigh
3/9/2020GuggenheimInitiated CoverageNeutralHigh
2/28/2020BenchmarkReiterated RatingBuy$135.00High
2/12/2020HC WainwrightReiterated RatingBuy$237.00Low
2/10/2020Roth CapitalLower Price TargetBuy$185.00 ➝ $180.00Medium
2/6/2020BenchmarkInitiated CoverageBuy$135.00Low
1/29/2020Roth CapitalLower Price Target$190.00 ➝ $185.00Low
1/16/2020HC WainwrightReiterated RatingBuy$214.00Medium
1/3/2020HC WainwrightReiterated RatingBuy$214.00Low
9/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$110.00 ➝ $132.00High
8/5/2019BarclaysLower Price TargetEqual Weight$131.00 ➝ $110.00High
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$131.00High
6/10/2019ArgusSet Price TargetBuy$140.00Medium
5/3/2019HC WainwrightReiterated RatingBuy ➝ Buy$254.00 ➝ $214.00High
3/13/2019HC WainwrightReiterated RatingBuy$254.00Low
3/7/2019Roth CapitalLower Price TargetBuy$195.00 ➝ $180.00Low
3/6/2019HC WainwrightReiterated RatingBuy ➝ Buy$281.00 ➝ $254.00High
2/13/2019ArgusReiterated RatingBuy$200.00 ➝ $150.00Low
11/19/2018HC WainwrightSet Price TargetBuy$281.00High
11/5/2018HC WainwrightReiterated RatingBuy$281.00High
10/29/2018HC WainwrightSet Price TargetBuy$280.00Medium
10/29/2018Roth CapitalUpgradeNeutral ➝ Buy$250.00 ➝ $195.00Medium
10/18/2018HC WainwrightSet Price TargetBuy$280.00Low
10/2/2018HC WainwrightBoost Price TargetBuy ➝ Buy$270.00 ➝ $280.00Medium
9/19/2018HC WainwrightSet Price TargetBuy$257.00 ➝ $270.00Low
9/11/2018ArgusSet Price TargetBuy ➝ Buy$260.00 ➝ $300.00Low
8/17/2018The Goldman Sachs GroupInitiated CoverageNeutral$256.00High
8/8/2018Roth CapitalReiterated RatingBuy ➝ NeutralHigh
8/8/2018StephensReiterated RatingBuy$248.00High
8/7/2018HC WainwrightReiterated RatingBuy$249.00Medium
8/7/2018Craig HallumBoost Price TargetBuy$230.00 ➝ $260.00Medium
7/27/2018HC WainwrightSet Price TargetBuy$249.00High
7/18/2018HC WainwrightSet Price TargetBuy$245.00High
6/28/2018HC WainwrightReiterated RatingBuyHigh
6/27/2018Craig HallumReiterated RatingBuy$230.00High
6/21/2018ArgusInitiated CoverageBuyLow
5/9/2018HC WainwrightReiterated RatingBuy$182.00High
3/7/2018HC WainwrightBoost Price TargetBuy ➝ Buy$170.00 ➝ $182.00Medium
3/7/2018Craig HallumReiterated RatingBuy$190.00 ➝ $200.00Medium
2/26/2018Roth CapitalBoost Price TargetBuy$158.00 ➝ $171.00Low
2/22/2018Craig HallumBoost Price TargetBuy$170.00 ➝ $190.00Medium
2/2/2018HC WainwrightReiterated RatingBuy$170.00Low
1/24/2018HC WainwrightBoost Price TargetBuy ➝ Buy$159.00 ➝ $170.00Low
1/18/2018HC WainwrightReiterated RatingBuy$169.00Low
1/12/2018HC WainwrightSet Price TargetBuy$169.00Low
1/3/2018HC WainwrightSet Price TargetBuy ➝ Buy$169.00High
12/27/2017HC WainwrightSet Price TargetBuy ➝ Buy$163.00 ➝ $169.00Medium
11/28/2017HC WainwrightSet Price TargetBuy$163.00Low
11/22/2017HC WainwrightReiterated RatingBuy$159.00N/A
11/20/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$105.00N/A
11/15/2017Craig HallumReiterated RatingBuy$160.00 ➝ $170.00N/A
11/15/2017HC WainwrightSet Price TargetBuy$159.00N/A
11/13/2017Roth CapitalSet Price TargetBuy$158.00N/A
11/6/2017HC WainwrightReiterated RatingBuy$157.00N/A
10/24/2017HC WainwrightSet Price TargetBuy$157.00N/A
10/18/2017HC WainwrightSet Price TargetBuy$157.00N/A
10/11/2017Roth CapitalReiterated RatingBuy$135.00 ➝ $158.00N/A
10/5/2017HC WainwrightReiterated RatingBuy$157.00N/A
9/5/2017HC WainwrightReiterated RatingBuy ➝ Buy$150.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/15/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/14/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Ligand Pharmaceuticals logo
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $106.36
Low: $102.18
High: $106.69

50 Day Range

MA: $89.95
Low: $74.52
High: $106.09

52 Week Range

Now: $106.36
Low: $72.57
High: $169.98

Volume

83,812 shs

Average Volume

149,832 shs

Market Capitalization

$1.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Ligand Pharmaceuticals?

The following equities research analysts have issued research reports on Ligand Pharmaceuticals in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Craig Hallum, HC Wainwright, Stephens, and StockNews.com.
View the latest analyst ratings for LGND.

What is the current price target for Ligand Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Ligand Pharmaceuticals in the last year. Their average twelve-month price target is $177.40, suggesting a possible upside of 66.8%. HC Wainwright has the highest price target set, predicting LGND will reach $310.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $130.00 for Ligand Pharmaceuticals in the next year.
View the latest price targets for LGND.

What is the current consensus analyst rating for Ligand Pharmaceuticals?

Ligand Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LGND will outperform the market and that investors should add to their positions of Ligand Pharmaceuticals.
View the latest ratings for LGND.

What other companies compete with Ligand Pharmaceuticals?

How do I contact Ligand Pharmaceuticals' investor relations team?

Ligand Pharmaceuticals' physical mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 550-7500 and its investor relations email address is [email protected] The official website for Ligand Pharmaceuticals is www.ligand.com. Learn More about contacing Ligand Pharmaceuticals investor relations.